EP-1137 DW MRI as biomarker of response during RT for intermed/high risk SCC oropharynx : a feasibility study

Tools

Paterson, C. and McCrea, I. and Hay, L. and Allwood-Speirs, S. and Devlin, L. and Sankaralingam, M. and McLoone, P. and Wilson, C. and Grose, D. and James, A. and Lamb, C. and Rizwanullah, M. and Schipani, S. and Nixon, Ioanna and Thomson, M. and McJury, M. and Foster, J. and Duffton, A. (2019) EP-1137 DW MRI as biomarker of response during RT for intermed/high risk SCC oropharynx : a feasibility study. Radiotherapy and Oncology, 133. S631-S632. (https://doi.org/10.1016/S0167-8140(19)31557-9)

[thumbnail of Paterson-etal-RO-2019-EP-1137-DW-MRI-as-biomarker-of-response-during-RT-for-intermed-high-risk-SCC-oropharynx]
Preview
 Text. Filename: Paterson_etal_RO_2019_EP_1137_DW_MRI_as_biomarker_of_response_during_RT_for_intermed_high_risk_SCC_oropharynx.pdf
Final Published Version
License: Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 logo
Download (207kB)| Preview

Abstract

Despite radical chemo-radiotherapy (CRT), many patients with intermediate and high risk SCC oropharynx (OPSCC) relapse. Treatment related toxicity limits further uniform intensification across the patient group. If a predictive biomarker for outcomes from CRT can be identified during treatment, individualised and adaptive treatment strategies may be employed for the non-responders. This is the 1st study to use DW MRI for early response assessment in a specific H&N sub-site with sub-type of similar biological behaviour.

ORCID iDs

Paterson, C., McCrea, I., Hay, L., Allwood-Speirs, S., Devlin, L., Sankaralingam, M., McLoone, P., Wilson, C., Grose, D., James, A., Lamb, C., Rizwanullah, M., Schipani, S., Nixon, Ioanna ORCID logoORCID: https://orcid.org/0000-0003-3223-0700, Thomson, M., McJury, M., Foster, J. and Duffton, A.;
CORE (COnnecting REpositories)